The earnings call for Johnson & Johnson revealed a mixed bag of results for the first quarter of 2011. The company reported a 3.5% increase in worldwide sales, with operational growth of 1.8% and a positive currency impact of 1.7%. However, there were notable decreases in sales in the U.S. and the Consumer segment. The Pharmaceuticals segment saw strong operational growth of 6.4%, while the Medical Devices & Diagnostics segment grew 1.3% operationally. The Consumer segment saw a 4.1% decline in operational sales, with U.S. sales down 13.8% and international sales up 2.6%.

Key points from the call include:

1. **Pharmaceuticals Segment**: The Pharmaceuticals segment reported strong operational growth of 6.4%, driven by the success of recently launched products such as STELARA and SIMPONI. Sales of key immunology products, including REMICADE, STELARA, and SIMPONI, were up nearly 18% compared to 2010. LEVAQUIN, an anti-infective, saw a 16.9% increase in sales. The U.S. anti-infective market was estimated to be up over 8% in the quarter due to higher incidence of respiratory illness and flu.

2. **Medical Devices & Diagnostics Segment**: The Medical Devices & Diagnostics segment saw modest sales growth of 1.3% operationally. The DePuy franchise had operational growth of 1.7%, with the U.S. down 0.4% and the business outside the U.S. growing by 4.2%. The Diabetes franchise was up 6% operationally, with the U.S. business up 7.2% and the business outside the U.S. up 4.9% operationally. The Ethicon franchise achieved operational growth of 2.3%, with U.S. sales down 1.2% and sales outside the U.S. up 3.3% operationally.

3. **Consumer Segment**: The Consumer segment saw a 4.1% decline in operational sales, with U.S. sales down 13.8% and international sales up 2.6%. The OTC Pharmaceuticals and Nutritionals segment decreased 8.2% on an operational basis compared to the same period in 2010, with U.S. sales down 26.8%. The Skin Care business declined 3.7% on an operational basis, with sales in the U.S. down 5.8% and sales outside the U.S. down 1.7% operationally. The Baby Care products achieved operational growth of 3.1%, with cleansers, wipes, and powders outside the U.S. driving the growth. Women's Health declined 4% on an operational basis, with sales in the U.S. down 14.4% and sales outside the U.S. up 0.7%. Sales of K-Y products and the divestiture of the e.p.t. brand impacted growth in the quarter. Sales in the Oral Care franchise were flat on an operational basis, with sales in the U.S. down 6.3% and sales outside the U.S. increasing by 0.6% operationally, driven by strong growth for LISTERINE.

4. **Guidance**: The company provided guidance for 2011, with an expected operational sales increase of between 2.5% and 3.5% on a constant-currency basis. The company expects full year 2011 operational EPS estimates of between $4.74 and $4.84 per share, excluding the impact of special items. The company also expects net interest expense of between $300 million and $400 million for the year, and other income and expense of between $700 million and $800 million.

5. **Key Concerns**: The company is facing several challenges, including the impact of the McNeil Consumer Healthcare Consent Decree, the acquisition of Crucell, and the amended agreement with Merck. The McNeil Consent Decree is expected to have a $0.12 per share impact on earnings, with an additional $0.06 per share impact from the remediation efforts. The acquisition of Crucell is expected to have a $0.03 to $0.05 per share dilutive impact on earnings. The amended agreement with Merck is expected to have a minimal impact on earnings in 2011, with transitional items and the fact that the company expects to invest for future growth.

6. **Outlook**: The company remains optimistic about the prospects for the year, with the dedication, focus, and integrity of the people at Johnson & Johnson driving growth. The company is confident that the global economy will stabilize, and that new products, robust pipelines, and core businesses will continue to address the critical, unmet healthcare needs of patients and consumers.

Overall, the earnings call for Johnson & Johnson reveals a mixed bag of results for the first quarter of 2011. The company reported strong sales growth in the Pharmaceuticals segment, but faced challenges in the Consumer segment and the Medical Devices & Diagnostics segment. The company provided guidance for 2011, with an expected operational sales increase of between 2.5% and 3.5% on a constant-currency basis. The company is facing several challenges, including the impact of the McNeil Consumer Healthcare Consent Decree, the acquisition of Crucell, and the amended agreement with Merck. The company remains optimistic about the prospects for the year, with the dedication, focus, and integrity of the people at Johnson & Johnson driving growth.